Suppression of azoxymethane‐induced colon cancer development in rats by a cyclooxygenase‐1 selective inhibitor, mofezolac
- 27 July 2006
- journal article
- Published by Wiley in Cancer Science
- Vol. 97 (10), 1011-1014
- https://doi.org/10.1111/j.1349-7006.2006.00275.x
Abstract
We demonstrated recently that mofezolac, a cyclooxygenase-1 (COX-1) selective inhibitor, suppresses the development of azoxymethane (AOM)-induced colonic aberrant crypt foci in F344 rats and intestinal polyps in APC1309 mice. In the present study, we therefore investigated the effects of mofezolac on colon cancer development. Male F344 rats were injected subcutaneously with 15 mg/kg body weight of AOM in the back twice at 7-day intervals from 5 weeks of age, and fed a diet containing 600 or 1200 ppm mofezolac for 32 weeks, starting 1 day before the first dosing of AOM. Treatment with 1200 ppm mofezolac significantly reduced the incidence, multiplicity and volume of colon carcinomas to 79%, 2.15 +/- 1.65 and 7.5 +/- 11.8 mm3, respectively, compared with 94%, 3.19 +/- 1.87 and 23.7 +/- 31.2 mm3 in the AOM treatment alone. Administration of 600 ppm mofezolac showed only a slight reduction. No side effects were observed in any of the groups. These results confirm that COX-1, as well as COX-2, contributes to colon carcinogenesis and that mofezolac may be a good chemopreventive agent for human colon cancer.Keywords
This publication has 18 references indexed in Scilit:
- Roles of Prostanoids in Colon Carcinogenesis and their Potential Targeting for Cancer ChemopreventionCurrent Pharmaceutical Design, 2006
- Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial CancerCancer Research, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Downregulation of prostaglandin E receptor subtype EP3 during colon cancer developmentGut, 2004
- Combined effects of cyclooxygenase‐1 and cyclooxygenase‐2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout miceInternational Journal of Cancer, 2004
- Down‐regulation of cyclooxygenase‐2 expression but up‐regulation of cyclooxygenase‐1 in renal carcinomas of the Eker (TSC2 gene mutant) rat modelCancer Science, 2003
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Nimesulide, a Selective Anti-Inflammatory Cyclooxygenase-2 Inhibitor, Does Not Affect Polyp Number and Mucosal Proliferation in Familial Adenomatous PolyposisScandinavian Journal of Gastroenterology, 1999
- Suppression of Intestinal Polyp Development by Nimesulide, a Selective Cyclooxygenase-2 Inhibitor, in Min MiceJapanese Journal of Cancer Research, 1997
- Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulcerationCell, 1995